Ensign Peak Advisors, Inc Chinook Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $44,000 - $90,971	-2,358 Reduced 0.65%	359,480 $13.8 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $2.33 Million - $3.42 Million	124,933 Added 52.74%	361,838 $9.48 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $889,648 - $1.19 Million	50,808 Added 27.3%	236,905 $4.66 Million
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $887,580 - $1.4 Million	83,029 Added 80.56%	186,097 $3.04 Million
Q1 2021 May 12, 2021	BUY	$14.17 - $19.11 $475,828 - $641,713	33,580 Added 48.32%	103,068 $1.6 Million
Q4 2020 Feb 12, 2021	SELL	$11.9 - $20.91 $3.31 Million - $5.81 Million	-277,952 Reduced 80.0%	69,488 $1.1 Million
Q3 2020 Nov 12, 2020	BUY	$11.4 - $15.5 $3.96 Million - $5.39 Million	347,440 New	347,440 $845,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.